Equillium (EQ.O) gets Australian regulatory clearance for first-in-human clinical trial of Eq504
Equillium Inc expects to begin dosing patients in its first-in-human clinical trial of Eq504 in Australia by early November 2026, with topline Phase 1 data expected six months after study initiation.
Oct 5 (Reuters) — Equillium Inc: Equillium Receives Australian Regulatory Clearance To Initiate First-in-human Clinical Trial Of Eq504 Equillium - Expects To Begin Dosing By Early November 2026 Equillium - Topline Phase 1 Data Expected Six Months After Study Initiation Source text:... com;)